19/05/2013 14:01:29 Free Membership Login
Allergy Thera.
   

Allergy Therapeutics Company Financial Information
Allergy Therapeutics share price | Allergy Therapeutics company information | Allergy Therapeutics Share Charts | Allergy Therapeutics Share News
 Company name: Allergy Thera.
 EPIC: AGY Trading Currency: GBX
 Market Sector: AIM ISIN: GB00B02LCQ05
 Market Segment: AIM Share Type: DE
 WWW Address:  Description: ORD 0.1P
 Industry Sector: PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Ask Open High Low Volume
 10.13 mages.advfn.com/imagesnew/2/us/dot 0.0 [0.00] 9.75 10.50 10.13 10.13 10.13 -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 41.50 409.87 0.86 0.25 - 40.50 - 13.50 - 7.25

Allergy Therapeutics Key Figures

(at previous day's close)
Market Cap.41.50m
Shares In Issue409.87m
Prev. Close10.13
PE Ratio40.50 
Dividend Yield-%
EPS - basic0.25p
Dividend PS-p
Dividend Cover- 
Cash Flow PS0.70p
Return On Equity (ROE)5.64%
Operating Margin1.55%
PEG Factor- 
EPS Growth Rate-%
Dividends PS Growth Rate-%
Net Debt12.26m
Gross Gearing47.42%
Quick Assets6.38m
Net Working Capital5.29m
Intangibles / Fixed Assets31.22%
Turnover PS10.07p
Pre-Tax Profit PS0.16p
Retained Profit PS0.20p
Cash PS0.22p
Net Cash PS-1.67p
Net Tangible Asset Value PS *2.44p
Net Asset Value PS3.56p
Spread0.75 (7.14%) 
* Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies.

Allergy Therapeutics Balance Sheet

LSE:AGY:Liabilities+EQLSE:AGY:Assets

Allergy Therapeutics Share Price

Sample Period †HighLow
1 week10.2510.13
4 weeks10.6310.13
12 weeks11.0010.00
1 year13.507.25

Allergy Therapeutics Share Price (5 years)

Allergy Therapeutics Historic Returns

Giorni da oggi †OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week10.13--10.180.0410.22
4 weeks10.63-0.50-4.7110.341.4110.14
12 weeks10.13--10.460.4910.16
26 weeks13.13-3.00-22.8611.200.3711.16
1 year8.132.0024.6210.880.529.92
3 years10.25-0.13-1.2210.760.3210.39
5 years36.00-25.88-71.8812.460.2511.44
† periods calculated are whole weeks rather than calendar months

Allergy Therapeutics Key Management Ratios

Allergy Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio11.19 
PE Ratio40.50 
Tobin's Q Ratio 1.42 
Tobin's Q Ratio (excl. intangibles)1.68 
Dividend Yield-%
Market-to-Book Ratio2.84 
Price-to-Pre-Tax Profit PS64.84 
Price-to-Retained Profit PS50.42 
Price-to-Cash Flow PS14.41 
Price-to-Sales PS1.01 
Price-to-Net Tangible Asset Value PS4.15 
Price-to-Cash PS45.96 
Net Working Capital PS1.29 
Price Pct to Working Capital PS7.85%
Earnings Yield2.47%
Average PE44.25 
Years in average2 
PE to PE average91.53%

Allergy Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio27.07%
Debt-to-Equity Ratio0.37 
Debt-to-Equity Ratio (excl. Intgbl)0.54 
Debt-to-Equity Market Value0.13 
Net Gearing44.17%
Net Gearing (excl. Intangibles)52.94%
Gross Gearing47.42%
Gross Gearing (excl. Intangibles)56.84%
Gearing Under 1 Year27.91%
Gearing Under 1 Year (excl. Intgbl)33.45%
Assets/Equity1.90 
Cash/Equity6.19 
(Liquidity Ratios)
Net Working Capital to Total Assets19.05%
Current Ratio1.68 
Quick Ratio (Acid Test)0.82 
Liquidity Ratio0.12 
Cash & Equiv/Current Assets6.93%
(Solvency Ratios)
Enterprise Value46.01m
CFO/Sales0.07 
CFO/Attributable Profit3.50 
CFO/Assets0.10 
CFO/Debt0.22 
Total Debt/Equity Market Value0.32 
Total Debt/Sales0.32 
Total Debt/Pre-Tax Profit20.57 
Total Debt13.16m
Total Debt/Net Current Assets2.49%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth7.72%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs3 
Beta (60-Mnth)Beta (36-Mnth)
0.86160.1109
Alpha (60-Mnth)Alpha (36-Mnth)
-0.00290.0144

Allergy Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)3.20%
Return On Assets (ROA)2.82%
Net Profit Margin1.99%
Assets Turnover1.41 
Return On Equity (ROE)5.64%
Return On Investment (ROI)4.17%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio9.84%
Net Income Of Revenues1.99%
(Asset Utilisation Multiples)
Shareholders Equity Turnover4.93 
Fixed Assets Turnover2.71 
Current Assets Turnover2.95 
Net Working Capital Turnover 
Inventory Turnover6.15 
(Other Operating Ratios)
Total Assets-to-Sales0.71 
Debtors-to-Sales14.64%
Debt Collection Period53.42Days

Allergy Therapeutics Dividends

Sorry No Data Available

Allergy Therapeutics Fundamentals
 30 Jun 2009 (GBP)30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)
turnover37.76100.00%40.75100.00%41.55100.00%41.28100.00%m
pre tax profit-11.44-30.29%-0.12-0.28%-2.31-5.57%0.641.55%m
attributable profit-11.76-31.16%0.591.44%-2.66-6.41%0.821.99%m
retained profit-11.76-31.16%0.591.44%-2.66-6.41%0.821.99%m
eps - basic-14.30 0.20 -0.86 0.25 
eps - diluted-14.30 0.19 -0.86 0.24 
dividends per share- - - - 

Allergy Therapeutics Balance Sheet

 30 Jun 2009 (GBP)30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)
LSE:AGY:Liabilities+EQLSE:AGY:AssetsLSE:AGY:Liabilities+EQLSE:AGY:AssetsLSE:AGY:Liabilities+EQLSE:AGY:AssetsLSE:AGY:Liabilities+EQLSE:AGY:Assets
 30 Jun 2009 (GBP)30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)
ASSETS
fixed assets fixed assets7.1932.57%8.9430.70%8.8128.77%7.5627.22%m
intangibles intangibles3.6216.40%3.3611.53%4.4114.39%4.6016.56%m
fixed investments fixed investments1.828.26%2.026.93%2.498.14%2.579.26%m
current assets - other current assets - other--%--%--%0.481.74%m
stocks stocks6.0027.19%6.8923.68%6.7822.14%6.6523.96%m
debtors debtors3.4415.58%3.3911.64%7.0923.14%5.0018.00%m
cash & securities cash & securities--%4.5215.52%1.053.42%0.903.25%m
TOTAL22.08100%29.12100%30.62100%27.75100%m
LIABILITIES
creditors - short creditors - short21.7798.63%9.9834.29%11.1536.40%7.7527.91%m
creditors - long creditors - long23.48106.35%15.2552.36%17.3456.61%5.4219.51%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL45.25204.98%25.2386.65%28.4893.01%13.1647.42%m
EQUITY
ord cap, reserves ord cap, reserves-23.18-104.98%3.8913.35%2.146.99%14.5952.58%m
prefs, minorities prefs, minorities--%--%--%--%m
TOTAL-23.18-104.98%3.8913.35%2.146.99%14.5952.58%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Allergy Therapeutics Cash Flow Statement

30 Jun 2009 (GBP)30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)
Operating CF-0.441.70-2.032.88m
Pre-Financing CF-2.43-0.31-4.311.31m
Retained CF-2.324.59-3.55-1.42m

Allergy Therapeutics Brokers

NameActivityTypeMnemonicCode
Canaccord Genuity LimitedMarket Maker(MMF)Broker/DealerCANAHOARGB21001
Nomura Code Securities LimitedMarket Maker(MMF)Broker/DealerCODECODCGB21
Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MMF)Broker/DealerJEFFJEFFGB2X
Liberum Capital LimitedMarket Maker(MMF)Broker/DealerLIBCLCAPGB21
Piper Jaffray LtdMarket Maker(MMF)Broker/DealerPIPRPIPRGB21
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC



NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's

1 site:2 us lse agy130519 14:01